Fund Overview
ETF
Nippon India Nifty Pharma ETF
Ticker: PHARMABEESUnderlying Index: Nifty PharmaISIN: INF204KC1089
26.0413.08% (1Y)
End of Day NAV as on Oct 23, 2026
Fundamentals
| Asset Type | Equity |
| Underlying Index Type | Sectoral Index |
| No. of Companies | 20 Companies |
| Market Cap Focus | Multi / Flexi Cap |
| Std Deviation (1 yr) | 0.86% |
| P/E | 52.48 |
| P/B | 8.07 |
| Div Yield | 0.57% |
| Down from 52w High | 8.88% |
| Up from 52w Low | 20.06% |
| Asset Type | Equity |
| Underlying Index Type | Sectoral Index |
| No. of Companies | 20 |
| Market Cap Focus | Multi / Flexi Cap |
| P/E | 52.48 |
| P/B | 8.07 |
| Div Yield | 0.57% |
| Down from 52w High | 8.88% |
| Up from 52w Low | 20.06% |
| Std Deviation (1 yr) | 0.86% |
Fund Parameters
| AUM (Cr) | 1,736 |
| Base Expense Ratio | 0.18% |
| Tracking Error | 0.02% |
| All-In-Cost | 0.21% |
| Inception Date | 06 Jul 2021 |
| Scheme Option - Type | Growth - Open ended scheme |
| Latest Price | 25.89 |
| NAV Gap | -0.58% |
| 1M Average NAV Gap | 0.01% |
| Daily Volume | 41,19,128 |
| 1M Average Daily Volume | 44,03,376 |
| 1M Average Daily Turnover (Cr) | 11.9 |
Native Score
| AUM (Cr) | 1,736 |
| Base Expense Ratio | 0.18% |
| Tracking Error | 0.02% |
| All-In-Cost | 0.21% |
| Inception Date | 06 Jul 2021 |
| Scheme Option - Type | Growth - Open ended scheme |
| ETF Market Data | |
| Latest Price | 25.89 |
| NAV Gap | -0.58% |
| 1M Avg NAV Gap | 0.01% |
| Daily Volume | 41,19,128 |
| 1M Avg Daily Volume | 44,03,376 |
| 1M Avg Daily Turnover | 11.9 |
| Native Score | |
Similar Exchange Traded Funds (ETFs)
No similar exchange traded funds (etfs) available for this index
Similar Index Funds
| Fund Name | ||||||
|---|---|---|---|---|---|---|
| N/A | 163 | 0.32% | 0.06% | 0.38% |
Swipe to view more data →
| Fund Name | Last Close | AUM (Cr) | Avg Exp Ratio | Tracking Error | All-In-Cost | Score |
|---|---|---|---|---|---|---|
| N/A | 163 | 0.32% | 0.06% | 0.38% |
Sectoral Allocation
Total
100%
allocation
- Healthcare100.0%
- Miscellaneous0.2%
- Healthcare100.0%
- Miscellaneous0.2%
Fund Holdings
| Name | Weight |
|---|
| Sun Pharmaceutical Industries Ltd. | 19.5% |
| Divi's Laboratories Ltd. | 12.0% |
| Laurus Labs Ltd. | 7.8% |
| Cipla Ltd. | 7.7% |
| Dr. Reddy's Laboratories Ltd. | 7.6% |
| Torrent Pharmaceuticals Ltd. | 7.2% |
| Lupin Ltd. | 5.0% |
| Aurobindo Pharma Ltd. | 4.7% |
| Glenmark Pharmaceuticals Ltd. | 3.6% |
| Alkem Laboratories Ltd. | 3.2% |
| Zydus Lifesciences Ltd. | 2.9% |
| Mankind Pharma Ltd. | 2.9% |
| Ipca Laboratories Ltd. | 2.7% |
| Biocon Ltd. | 2.6% |
| Gland Pharma Ltd. | 2.3% |
| Sai Life Sciences Ltd. | 2.1% |
| Wockhardt Ltd. | 1.8% |
| Ajanta Pharma Ltd. | 1.7% |
| Abbott India Ltd. | 1.4% |
| Piramal Pharma Ltd. | 1.3% |
| Tri-Party Repo (TREPS) | 0.2% |
| Cash & Cash Equivalent | 0.0% |
| Net Current Asset | -0.1% |
NameWeight
Sun Pharmaceutical Industries Ltd.19.5%
Divi's Laboratories Ltd.12.0%
Laurus Labs Ltd.7.8%
Cipla Ltd.7.7%
Dr. Reddy's Laboratories Ltd.7.6%
Torrent Pharmaceuticals Ltd.7.2%
Lupin Ltd.5.0%
Aurobindo Pharma Ltd.4.7%
Glenmark Pharmaceuticals Ltd.3.6%
Alkem Laboratories Ltd.3.2%
Zydus Lifesciences Ltd.2.9%
Mankind Pharma Ltd.2.9%
Ipca Laboratories Ltd.2.7%
Biocon Ltd.2.6%
Gland Pharma Ltd.2.3%
Sai Life Sciences Ltd.2.1%
Wockhardt Ltd.1.8%
Ajanta Pharma Ltd.1.7%
Abbott India Ltd.1.4%
Piramal Pharma Ltd.1.3%
Tri-Party Repo (TREPS)0.2%
Cash & Cash Equivalent0.0%
Net Current Asset-0.1%
Holdings Concentration
Total covered: 100%
Top 1–5
5 holdings
54.6%
55%
share
Top 6–10
5 holdings
23.6%
24%
share
Top 11–20
10 holdings
21.8%
22%
share
Beyond 20
2 holdings
0.2%
0%
share
Market Cap Classification
Total
100%
allocation
- Large Cap46.3%
- Mid Cap46.1%
- Small Cap7.6%
- Large Cap46.3%
- Mid Cap46.1%
- Small Cap7.6%
Advanced Ratios
| Alpha | 0.00 |
| Beta | 1.00 |
| Sharpe Ratio | 0.09 |
| Sortino Ratio | 0.17 |
| Treynor Ratio | 0.08 |
| Information Ratio | 0.02 |
| Upside Capture | 99.80% |
| Downside Capture | 99.60% |
Index Methodology
| Factor Basis | Sector/Theme |
| What universe selected from? | Nifty 500 |
| Weightage? | Free-Float Market Cap Weighting; Max Weight per stock = 33% |
| Stocks Included | Max 20 stocks. Top 20 stocks from the Indian Pharma & Biotech sector are selected. |
| Exclusions | Constituents moving out of the Nifty 500 and currently part of the Nifty Pharma Index are excluded; |
| Factor Basis | Sector/Theme |
| Universe | Nifty 500 |
| Weightage | Free-Float Market Cap Weighting; Max Weight per stock = 33% |
| Stocks Included | Max 20 stocks. Top 20 stocks from the Indian Pharma & Biotech sector are selected. |
| Exclusions | Constituents moving out of the Nifty 500 and currently part of the Nifty Pharma Index are excluded; |
Fund • Last updated: 25/10/2026